secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001818382-23-000125
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte reports positive Phase 2/3 HAV trauma trial; BLA planned Q4 2023
-------------------------------------------------------------------------

- 30-day secondary patency 90.2% (extremity pts) vs 81.1% synthetic graft benchmark.
- Amputation rate 9.8% and infection rate 2.0%, both lower than synthetic graft rates.
- BLA filing for HAV in extremity vascular trauma expected in Q4 2023.
- No unexpected safety signals; results from Ukraine cohort also positive.
- HAV has RMAT designation, may allow priority review and no post-approval study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000125/0001818382-23-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000125/huma-20230912.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer